RCS - Ondine Biomedical - Ex-President of Mexico Champions APDT to Cut AMR

Ondine BiomedicalAnnouncement

Mon 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250811:nRSK7375Ua&default-theme=true

RNS Number : 7375U  Ondine Biomedical Inc.  11 August 2025

11 August 2025

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

Ex-President of Mexico Champions APDT to Cut AMR

Former Mexican President to Chair 'Light Against AMR Initiative' to Accelerate
Photodisinfection Adoption in High-Growth Regions

 

Ondine Biomedical Inc. (AIM: OBI), a global innovator in antimicrobial
photodynamic therapy (APDT, also known as photodisinfection), and the
International Photodynamic Association ("IPA") have launched a strategic
initiative to accelerate the deployment of affordable, light-based infection
control technologies in underserved, fast-growing and emerging markets.

The Light Against AMR Initiative will be led by former President of Mexico,
Vicente Fox, who will serve as Chair. President Fox's leadership marks a
pivotal moment in the global fight against antimicrobial resistance ("AMR"), a
mounting health and economic crisis. Widely recognized for expanding
healthcare access during his presidency, including the landmark Seguro Popular
program, he brings decades of experience in championing equitable healthcare.

Mr. Fox stated:

"Drug-resistant infections threaten lives and livelihoods across all nations.
Photodisinfection is a proven, accessible solution that can protect millions,
especially in regions where traditional antibiotics are failing.

"Ensuring affordable, life-saving care has been my lifelong mission.
Photodisinfection is a practical, cost-effective tool that can break the AMR
cycle. I am committed to making this technology available where it's needed
most."

AMR is a growing crisis that transcends borders, driven by antibiotic misuse
and inadequate infection control, particularly in regions with limited
healthcare infrastructure. Photodisinfection, an innovative, resistance-proof
approach that uses light-activated agents to eliminate pathogens, offers an
immediate, scalable alternative to antibiotics.

Dr. Colin Hopper, President of the IPA, underscored the urgency:

"By 2050, AMR is projected to surpass cancer in mortality, claiming 10 million
lives annually. President Fox's leadership will be instrumental in deploying
photodisinfection to regions on the frontline of this silent pandemic."

Carolyn Cross, CEO of Ondine Biomedical, commented:

"This collaboration is a major milestone in our mission to establish
photodisinfection as a global standard. Partnering with President Fox and the
IPA accelerates our strategy to bring Ondine's innovative, cost-effective
solutions to high-growth regions, where the burden of AMR is most severe."

The Light Against AMR Initiative builds on three decades of global APDT
expertise and aims to unite researchers, healthcare systems, and policymakers
to overcome access barriers. It will focus on combating multidrug-resistant
pathogens such as multidrug-resistant pathogens such as E.
coli, Staphylococcus aureus, Klebsiella pneumoniae,
and Enterococcus species, delivering effective interventions at a fraction
of the cost of new antibiotics.

 

Enquiries:

 Ondine Biomedical Inc.                              www.ondinebio.com (http://www.ondinebio.com)
 Carolyn Cross, CEO                                  +1 604 669 0555

or via Vane Percy & Roberts

 Strand Hanson Limited (Nominated & Joint Financial Adviser)
 James Harris, Richard Johnson                       +44 (0)20 7409 3494

 Peel Hunt LLP (Broker and Joint Financial Adviser)
 James Steel, Dr. Chris Golden                       +44 (0)20 7418 8900

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy                                    +44 (0)77 1000 5910

 

 

About the International Photodynamic Association (IPA)

Founded in 1986, the International Photodynamic Association (IPA) is a global
organization dedicated to advancing the research, education, and clinical use
of photodynamic technologies across medical and biological fields. With
members in over 30 countries, the IPA brings together a worldwide community of
leading scientists, clinical and translational researchers, healthcare
professionals, and students from academia, hospitals, government and industry.

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in
light-activated antimicrobial therapies ('photodisinfection') for the
prevention and treatment of infections, including those caused by
multidrug-resistant organisms. Ondine has a pipeline of investigational
products, based on its proprietary photodisinfection technology, in various
stages of development.

Ondine's nasal photodisinfection system has a CE mark in Europe and is
approved in Canada, Australia, Mexico and several other countries under the
name Steriwave(®). In the US, it has been granted Qualified Infectious
Disease Product designation and Fast Track status by the FDA and is currently
undergoing clinical trials for regulatory approval. Products beyond nasal
photodisinfection include therapies for a variety of medical indications such
as chronic sinusitis, ventilator-associated pneumonia, burns and other
indications.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAKBLFFEVLZBBL